Bepirovirsen Studied for Treatment of Chronic Hepatitis B Infection

MONDAY, Nov. 14, 2022 -- A 300-mg dose of bepirovirsen per week for 24 weeks results in sustained hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA loss in 9 to 10 percent of patients with chronic HBV infection, according to a...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news